Swiss majors Roche and Novartis back gene therapy upstart – FierceBiotech
FierceBiotech |
Swiss majors Roche and Novartis back gene therapy upstart
FierceBiotech Newly born European biotech Vivet Therapeutics has started life with €37.5 million ($41 million) and an exec team made up of Novartis, Sanofi and Gensight vets, as the company looks to get to work on its gene therapies for a host of rare diseases … News Vivet Raises €37.5M to Develop Gene Ther… Novartis, Roche back French gene therapy start-up Vivet French Gene Therapy Biotech Raises a Huge €37.5M in Series A |
